Vascular Biogenics Ltd. operating as VBL Therapeutics
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
90.9%
+4.4% vs industry average
17%
2 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Role: collaborator
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Role: lead
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
Role: lead
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Role: lead
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Role: lead
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Role: lead
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Role: lead
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis
Role: lead
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Role: lead
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
Role: lead
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
Role: lead
Study to Assess VB-201 in Patients With Psoriasis
Role: lead
All 12 trials loaded